We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us


SCIEX develops and sells scientific instrumentation, software, and services for the life science, clinical research, ... read more Featured Products: More products

Download Mobile App

Serum Prostate-Specific Antigen Measured by Tandem Mass Spectrometry

By LabMedica International staff writers
Posted on 23 Oct 2014
Print article
AB Sciex\' API 5000 triple quadruple mass spectrometer
The API 5000 triple quadruple mass spectrometer (Photo courtesy of Sciex)
Prostate-specific antigen (PSA) is a widely used blood test for detection and monitoring of prostate disease and many clinicians assume that all test methods produce essentially the same results, though differences do exist.

PSA is a 34-kDa glycoprotein with chymotrypsin-like enzyme activity that circulates both in free forms and complexed to various enzyme inhibitors including anti-chymotrypsin and α2-macroglobulin. Prostate-specific antigen bound to α2-macroglobulin is not detected by commercial PSA immunoassays.

Scientists at the Mayo Clinic College of Medicine (Rochester, MN, USA) developed a strategy to use a mass spectrometry (MS) assay to measure PSA concentrations that measures only the immune-reactive forms. Prostate-specific antigen is immune extracted from serum using antibodies directed to different PSA epitopes. A combination of three monoclonal anti-PSA antisera, which are directed to different PSA epitopes, was used for immune extraction of PSA from serum. PSA was extracted from serum, trypsin digested, and the LSEPAELTDAVK peptide was quantitated.

Absolute quantitation was performed by liquid chromatography–tandem mass spectrometry using a CTC Analytics HTC PAL auto sampler (LEAP Technologies; Carrboro, NC, USA; www.leaptec.com), a Shimadzu 10-AD binary pumping system (Shimadzu Scientific Instruments; Columbia, MD, USA), and an API 5000 triple quadruple mass spectrometer (AB SCIEX; Framingham, MA, USA). Validation of clinical utility and comparisons with two immunoassays were performed using frozen sera aliquots from 100 men undergoing prostate biopsy, 50 negative, 50 with cancer, and five serial samples collected over time from five men with advanced prostate cancer.

The antibody extraction efficiency was greater than 99%. The assay has an analytic range from 1.2 to 76 ng/mL, with precision ranging from 8.6% at 1.5 ng/mL to 5.4% at 27 ng/mL. The mass spectrometry assay correlated well with the two commercial immunoassays. All three assays showed statistically equivalent separation of prostate cancer from benign disease using receiver operating characteristic curve analysis.

The authors concluded that their MS assays are the first potential reference mass spectrometry assays that measure the same forms of PSA as the commercial immunoassays. These assays can reliably quantitate PSA concentrations in male sera that closely match existing immunoassays, and these assays are traceable to the international PSA standard with the proteins and therefore make the measurement system incomplete. Another advantage of their immune extraction is the increase in the relative concentration of PSA caused when the peptides from the PSA in a larger sample of serum are re-suspended in a smaller injection volume of buffer for the MS. This increase in concentration helps improve the robustness of the MS assay. The study was published on the October 2014 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:

Mayo Clinic College of Medicine
LEAP Technologies

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Hemoglobin Testing System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
Click here to Register




view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.